Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇦🇪AE · Science#111500 to 3K
- 🇮🇱IL · Science#112500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
300 to 1.8K🎙 Daily cadence·97 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 6K🇦🇪50%🇮🇱50% - Active Followers
Loyal subscribers who consistently listen
400 to 2.4K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 13 epsHosts
Recent guests
Recent episodes
HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Jun 23, 2026
Unknown duration
Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
Jun 22, 2026
Unknown duration
Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
Jun 20, 2026
Unknown duration
HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy
Jun 11, 2026
58m 22s
Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
Jun 2, 2026
22m 50s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/23/26 | HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:Introduction (0:00)Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51)CME information and select publications | — | ||||||
| 6/22/26 | Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper | Featuring an interview with Prof Bernd Kasper, including the following topics:Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00)Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04)Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58)Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19)CME information and select publications | — | ||||||
| 6/20/26 | Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics:Introduction (0:00)Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08)Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20)CME information and select publications | — | ||||||
| 6/11/26 | HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy✨ | metastatic breast cancerER-positive+4 | Dr Sara A HurvitzDr Virginia Kaklamani | Fred Hutchinson Cancer CenterUT Health San Antonio MD Anderson Cancer Center | Seattle, WashingtonSan Antonio, Texas | breast cancermetastatic+5 | — | 58m 22s | |
| 6/2/26 | Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper✨ | desmoid tumorstreatment strategies+3 | Prof Bernd Kasper | Mannheim Cancer Center | Mannheim, Germany | desmoid tumorstreatment+3 | — | 22m 50s | |
| 4/30/26 | Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances✨ | breast cancerclinical trials+4 | Dr Aditya BardiaDr Erica Mayer | University of California Los AngelesDana-Farber Cancer Institute | Boston, Massachusetts | oral SERDsbreast cancer+4 | — | 57m 18s | |
| 4/16/26 | HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making✨ | HR-positive metastatic breast cancerbiomarker assessment+3 | Dr Seth Wander | Massachusetts General Hospital | — | HR-positivemetastatic breast cancer+4 | — | 1h 00m 13s | |
| 4/14/26 | ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy✨ | metastatic breast cancerfirst-line therapy+3 | Dr Virginia F BorgesDr Ian E Krop | University of Colorado Anschutz Medical CampusYale Cancer Center | — | ER-positiveHER2-positive+5 | — | 57m 59s | |
| 4/7/26 | Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan✨ | desmoid tumorsclinical data+4 | Dr Ravin Ratan | The University of Texas MD Anderson Cancer Center | — | desmoid tumorsclinical data+5 | — | 28m 14s | |
| 3/30/26 | Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway✨ | hyperglycemiabreast cancer+4 | Ms Jaime CarrollProfessor Giuseppe Curigliano+2 | Mayo ClinicEuropean Institute of Oncology+2 | Rochester, MinnesotaMilan, Italy+2 | hyperglycemiabreast cancer+6 | — | 1h 15m 32s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/18/26 | Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays✨ | breast cancercirculating tumor DNA+3 | Dr Lajos Pusztai | Yale Cancer Center | New Haven, Connecticut | breast cancercirculating tumor DNA+3 | — | 30m 21s | |
| 3/16/26 | Desmoid Tumors — Microlearning Activity 1 with Dr Ravin Ratan✨ | desmoid tumorsclinical data+3 | Dr Ravin Ratan | The University of Texas MD Anderson Cancer Center | — | desmoid tumorsclinical data+5 | — | 16m 43s | |
| 3/2/26 | Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances✨ | breast cancerclinical trials+3 | Dr Hope S RugoDr Sara M Tolaney | City of Hope Comprehensive Cancer CenterDana-Farber Cancer Institute | Duarte, CaliforniaBoston, Massachusetts | breast cancerantibody-drug conjugates+3 | — | 58m 40s | |
| 1/27/26 | Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series✨ | HR-positive breast cancerendocrine-based therapy+3 | Dr Angela DeMicheleDr Komal Jhaveri+3 | Abramson Cancer CenterMemorial Sloan Kettering Cancer Center+3 | Philadelphia, PennsylvaniaNew York, New York+2 | breast cancerendocrine therapy+3 | — | 2h 01m 07s | |
| 1/14/26 | HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series✨ | HER2-positive breast cancerclinical data+3 | Prof Giuseppe CuriglianoProf Nadia Harbeck+3 | University of MilanLMU University Hospital+3 | — | HER2-positivebreast cancer+5 | — | 1h 58m 18s | |
| 1/8/26 | Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series✨ | breast cancerantibody-drug conjugates+3 | Dr Javier CortésDr Rita Nanda+2 | International Breast Cancer CenterUniversity of Chicago+2 | Barcelona, SpainLondon, United Kingdom | breast cancerantibody-drug conjugates+3 | — | 1h 30m 21s | |
| 12/23/25 | Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases | Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.CME information and select publications here. | — | ||||||
| 12/8/25 | Breast Cancer — Highlights from the 2025 ESMO Annual Meeting | Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. CME information and select publications here. | — | ||||||
| 12/5/25 | Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates | Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here. | — | ||||||
| 12/2/25 | Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates | Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here. | — | ||||||
| 11/29/25 | Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2 | Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. CME information and select publications here. | — | ||||||
| 11/26/25 | Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates | Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here. | — | ||||||
| 11/20/25 | HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders | Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here. | — | ||||||
| 11/14/25 | ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs | Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here. | — | ||||||
| 11/10/25 | Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute | Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. CME information and select publications here. | — | ||||||
Showing 25 of 103
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.